This panel seeks to get to the bottom of the IFR and what it means for the hemp CBD industry currently and in the future. We may also touch on the intersection of USDA and FDA authority to regulate hemp-derived CBD products.
Hear from the panel about what “also advise” means in practice, including what federal laws are considered “related,” how to determine if federal law “conflicts” with what your client seeks to do, and how to ensure you have adequately advised your client to comply with the new Rule 1.2 provision.
This panel will discuss, among other things: (i) the goals of implementing solid corporate governance infrastructure including transparency, equity among shareholders, and maintaining the integrity and legitimacy of a cannabis company in particular; (ii) the importance of advising clients about best practices for effectively maintaining and enforcing corporate governance systems by, including, but not limited to, adhering to the often-overlooked federal guidelines from the United States Sentencing Commission; and (iii) the importance of implementing corporate governance controls and policies during a company’s infancy; and (iv) lessons learned from high-profile cannabis companies whose poor corporate governance practices had a damaging impact, including companies like Namaste Technologies.